{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":300,"width":600,"title":"Residual Risk in CAD: What Remains, Why It Matters, What to Do \ud83e\udec0\u26a0\ufe0f\ud83d\udca1","description":"\ud83e\udec0 Residual Risk in Coronary Artery Disease Even after \u201coptimal\u201d therapy, many patients remain at risk. Why? Because atherosclerosis is more than LDL\u2014it\u2019s thrombosis \ud83e\ude78, inflammation \ud83d\udd25, and metabolism \u2696\ufe0f working in concert. &amp;nbsp; This FAQ-based slide deck distills contemporary insights on residual thrombotic, lipid, metabolic, and inflammatory risk, and highlights emerging therapies\u2014from dual-pathway inhibition \ud83d\udc8a to GLP-1 receptor agonists \ud83e\uddec and colchicine\u2014that help close the gap between treatment and outcomes. &amp;nbsp; \ud83d\udcca Key message: precision, not complacency. #Cardiology #SecondaryPrevention #ResidualRisk #CAD #PrecisionMedicine ","author_name":"Dr. RR Baliga's 'Podkast for the Kurious Doc'","author_url":"http:\/\/www.MasterMedFacts.com","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/39988220\/height\/300\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"300\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/198207820"}